De Novo Pharmaceuticals Ltd Announces Drug Design and Discovery Partnership with Organon.
CAMBRIDGE, UK, March 9 /PRNewswire/ -- De Novo Pharmaceuticals Ltd (Cambridge, UK) (De Novo) announced today that it has entered a collaboration with Organon under De Novo's Drug Design Partnership Program. Under the terms of the agreement, full details of which are being kept confidential,...

SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB(TM) Process in Drug Discovery and Design.
PRAGUE, Czech Republic, Nov. 9 /PRNewswire-FirstCall/ -- SuperGen Inc. today announced the presentation of four posters describing preclinical data on MP-529, one of the company's selected lead compounds, and several discovery programs during the scientific sessions at the 18th EORTC- NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. ...

Provid to Acquire Tripos Discovery Research.
NORTH BRUNSWICK, N.J., Jan. 5 /PRNewswire/ -- Provid Pharmaceuticals Inc. is pleased to announce that it has signed a definitive agreement to acquire Tripos Discovery Research (TDR), the UK-based drug discovery division of Tripos, Inc. Provid's management and scientific leadership team believes that a shared future with TDR will...

Locus Discovery Assembles One of the Most Powerful Supercomputers in the World.
Company Relocates and Moves Into a New State-of-the-Art Facility in Blue Bell, Pennsylvania BLUE BELL, Pa., July 25 /PRNewswire/ -- Locus Discovery Inc., a new computational drug design biopharmaceutical company, announced today that the Company has moved into a newly designed, state-of-the-art facility...

Southern Research CEO Jack Secrist Recognized for Contributions in Cancer Drug Research.
Receives the 2006 John A. Montgomery Award in Switzerland BIRMINGHAM, Ala., Nov. 13 /PRNewswire/ -- Southern Research Institute -- a not-for-profit organization that conducts basic and applied scientific and engineering research-today announced that its president and CEO, John A. "Jack" Secrist, III, Ph.D., has been named the...

Determination of ionization constant (p[K.sub.a]) and octanol--water partition coefficient (Log P) of cyclopiazonic acid.
The ionization constant (p[K.sub.a]) and the octanol-water partition coefficient (log P) of the important mycotoxin cyclopiazonic acid (CPA) were determined by means of potentiometric titration, and the lipophilicity profile (log D) was calculated. Under the experimental conditions, p[K.sub.a] of CPA = 2.97 [+ or -] 0.09, log P =...

GENEFORMATICS/DE NOVO FORM DRUG DISCOVERY COLLABORATION.
GeneFormatics Inc., San Diego, Calif., and De Novo Pharmaceuticals, Cambridge, U.K., have formed a collaborative drug discovery program to elucidate inhibitors of matrix metalloproteinases, specifically the M10 family. Matrix metalloproteinases are a family of naturally occurring enzymes involved in tissue growth and wound repair. Overproduction causes a...

Triad Therapeutics Combines Structural Proteomics and Smart Chemistry To Accelerate Small Molecule Drug Discovery From Years to Weeks.
Company Presents IOPE(TM) High Throughput Drug Design Technology at Drug Discovery Technology Europe Conference STUTTGART, Germany, April 24 /PRNewswire Interactive News Release/ -- Triad Therapeutics, Inc., today presented IOPE(TM), its high throughput structure-based drug design technology, as a solution to the chemistry bottleneck of post-genomics...

ArQule and Nanodesign Enter into Collaboration for Novel Drug Design Technology.
WOBURN, Mass., and GUELPH, Ontario, Jan. 16 /PRNewswire/ -- ArQule, Inc. (Nasdaq: ARQL) and Nanodesign Inc. ("Nanodesign"), a wholly owned subsidiary of SignalGene Inc. (Toronto: SGI), announced today that they have entered into a collaboration to develop and apply a novel compound design platform for drug discovery....

Jubilant and BioLeap Announce New Partnership in Drug Discovery.
NOIDA, India and NEW HOPE, Pa., Jan. 13 /PRNewswire/ -- Jubilant Organosys Ltd., headquartered at Noida, near New Delhi, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a drug discovery partnership with BioLeap, LLC, USA. Under this partnership, BioLeap and Jubilant will integrate BioLeap's leading...